

**Avacta Group plc**

("Avacta" or the "Group" or the "Company")

**Posting of Annual Report and Revised Notice of AGM**

**LONDON and PHILADELPHIA - June 9, 2025 - Avacta Therapeutics (AIM: AVCT)**, a life sciences company developing innovative, targeted oncology drugs, today announces

that its Annual Report and Accounts for the year ended December 31, 2024 and the Notice of Annual General Meeting ("AGM") are available on the Company's website at <https://avacta.com/investors/investor-resources/>.

Copies of the Annual Report and Accounts and the Notice of AGM will be posted today to registered shareholders who have elected to receive them in paper form.

The Company had intended to hold the AGM on Monday, June 30, 2025 however due to some logistical considerations and investor feedback on the prior date, the Company will now convene the AGM for Wednesday, July 2, 2025 at 9:00 am BST. The meeting will be held at the offices of Peel Hunt LLP, 7<sup>th</sup> Floor, 100 Liverpool Street, London EC2M 2AT (the "Venue").

The Venue has a capacity of approximately 120 people. Registered shareholders have a right to attend the AGM. In addition, the current expectation is that the chair of the AGM will, at their discretion, permit beneficial shareholders to attend in person. Shareholders (registered or beneficial) who propose to attend the AGM in person are requested to pre-register their interest and, to assist the Company in its preparation for the AGM, prove their shareholding by emailing their letter of representation to ICR at [avacta@icrhealthcare.com](mailto:avacta@icrhealthcare.com) by Friday, June 27, 2025. Any failure to pre-register will not, of itself, preclude a registered shareholder from attending the AGM in person (or by proxy).

Only registered shareholders who attend in person or by proxy will be able to vote on the day. Details of how to submit a proxy vote are contained in the Notice of the AGM.

The Company will provide a business update following the AGM, which will be recorded and uploaded on the Company's website for shareholders who are not able to attend in person. All presentation materials will be made available on the website at the end of the day and no new material information will be provided.

Early pre-registration to attend the AGM in person is recommended as the venue's capacity is limited (as referred to above) and, for non-registered shareholders, registrations will be dealt with on a first come, first served basis. Those attending in person are also recommended to arrive around 30 minutes before the start of the meeting to ensure that the venue's admission procedures can be adhered to.

**-Ends-**

**For further information from Avacta Group plc, please contact:**

**Avacta Group plc**  
Michael Vinegrad, Group Communications  
Director

<https://avacta.com/>

**Peel Hunt (Nomad and Joint Broker)**  
James Steel / Chris Golden

[www.peelhunt.com](http://www.peelhunt.com)

**Panmure Liberum (Joint Broker)**  
Emma Earl / Will Goode / Mark Rogers

<https://panmureliberum.com/>

**ICR Healthcare**  
Mary-Jane Elliott / Jessica Hodgson /  
Stephanie Cuthbert

[avacta@icrhealthcare.com](mailto:avacta@icrhealthcare.com)

**Investor Contact**  
Renee Leck  
THRUST Strategic Communications

[renee@thrustsc.com](mailto:renee@thrustsc.com)

**Media Contact**  
Carly Scaduto  
Carly Scaduto Consulting

[Carly@carlyscadutoconsulting.com](mailto:Carly@carlyscadutoconsulting.com)

**About Avacta** - [www.avacta.com](http://www.avacta.com)

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSB LGDLUBGDGUC